Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma
With systemic chemotherapy, GNAS-mutated metastatic/recurrent AAs have worse EFS despite less frequent high-risk features. Routine somatic mutation-testing of patients with AA should be considered for prognostication and possibly therapeutic decision-making.
Authors
- Erika Belmont (ORCID: https://orcid.org/0000-0002-7803-6383)
- Christopher Rodman
- Rushabh Gujarathi (ORCID: https://orcid.org/0000-0002-1748-6508)
- Varun Bansal (ORCID: https://orcid.org/0000-0002-9973-0884)
- Oliver S. Eng (ORCID: https://orcid.org/0000-0003-0226-5005)
- Namrata Setia (ORCID: https://orcid.org/0000-0002-6060-4717)
- Mecker Moller
- Lindsay Alpert
- Kiran K. Turaga
- Ardaman P. Shergill
- Grace Lee
- Blase N. Polite
- John Hart
Institutions
- University of Louisville (US)
- University of California, Irvine (US)
- Washington University in St. Louis (US)
- Yale University (US)
- University of Chicago (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1245/s10434-025-18805-5
- Citations
- 1
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 39.15